{"id":213042,"date":"2026-08-20T10:48:43","date_gmt":"2026-08-20T05:18:43","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=213042"},"modified":"2026-08-20T10:48:45","modified_gmt":"2026-08-20T05:18:45","slug":"under-the-radar-pharma-stocks-india","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/under-the-radar-pharma-stocks-india\/","title":{"rendered":"5 Under the Radar Pharma Stocks in India"},"content":{"rendered":"

5 under-the-radar pharma stocks: MCap Rs 14,787-46,260 Cr. 3 trade below sector PE 37.21. Best ROE: 23.33% (Ajanta Pharma). Lowest D\/E: 0.00 (Caplin Point). <\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The 5 pharma stocks flying under the radar in India are Caplin Point Laboratories, Neuland Laboratories, Marksans Pharma, Sudeep Pharma, and Ajanta Pharma. These companies operate in Latin American exports, API manufacturing, branded generics in UK and Australia, specialty pharma, and branded dermatology exports. Three of the five trade below the sector PE of 37.21. For investors looking past Sun Pharma and Cipla, these five are worth researching.<\/p>\n<\/div>\n

Under the radar pharma stocks in India rarely get the analyst note that follows every new USFDA plant reinspection result at Sun Pharma or a US generic filing at Cipla. Yet several mid-tier Indian pharmaceutical companies are building strong export pipelines, maintaining USFDA and EU GMP compliance, and delivering consistent ROE without the crowded institutional ownership of the large-cap pharma names.<\/p>\n

India’s pharmaceutical industry is the world’s third-largest by volume, and the export opportunity in branded generics, API, and emerging market supply is growing steadily. The five overlooked pharma stocks below each serve differentiated parts of this ecosystem, with data .<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n